Current uses of isolated limb perfusion in the clinic and a model system for new strategies

Lancet Oncology

Volumn 4, Issue 7, 2003, Pages 429-437

  Eggermont, Alexander M M ^a   de Wilt, Johannes H W ^a   ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; CYTOSTATIC AGENT; DACTINOMYCIN; DOXORUBICIN; GAMMA INTERFERON; HISTAMINE; INTERLEUKIN 3; MELPHALAN; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER LOCALIZATION; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG UPTAKE; HIGH RISK PATIENT; HUMAN; HYPERTHERMIA; HYPOXIA; LIMB AMPUTATION; LIMB PERFUSION; LIMB TUMOR; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 0037627840     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01141-0     Document Type: Review

References (75)

1. Creech O, Krementz E, Ryan E, Winblad J. Chemotherapy of cancer: regional perfusion utilising an extracorporeal circuit. Ann Surg 1958; 148: 616-32.
2. Benckhuijsen C, Kroon BB, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157-63.
3. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227-33.
4. Klaase JM, Kroon BBR, Van Geel AN, et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80: 1124-26.
5. Wieberdink K, Benckhuijsen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-10.
6. Eggermont AMM. Treatment of melanoma intransit metastases confined to the limb. Cancer Surv 1996; 26: 335-49.
7. Omlor G, Gross G, Ecker KW, et al. Optimization of isolated hyperthermic limb perfusion. World J Surg 1993; 16: 1117-19.
8. Cavaliere R, Ciocatto RC, Giovanella BC, et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 1967; 20: 1351-81.
9. Clark J, Grabs AJ, Parsons PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusions of melanoma. Melanoma Res 1994; 4: 365-70.
10. Klaase JM, Kroon BBR, Van Wijk J, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994; 178: 564-72.
11. Klaase JM, Kroon BBR, Van Geel AN, et al. A retrospective comparative study evaluating the results of a single perfusion versus a double perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71: 2990-94.
12. Rosin RD, Westbury G: Isolated limb perfusion for malignant melanoma. Practitioner 1980; 224: 1031-36.
13. Lejeune FJ, Deloof T, Ewalenko P. Objective regression fo unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 1983; 86: 268-76.
14. Minor DR, Allen RE, Alberts D, et al. A clinical and pharmokinetic study of isolted limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55: 2638-44.
15. Skene AI, Bulman AS, Williams TR, et al. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77: 765-67.
16. Kettelhack Ch, Kraus Th, Hupp Th, et al. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 1990; 16: 370-75.
17. Klaase JM, Kroon BBR, Eggermont AMM, et al. A retrospective comparative study evaluating the results of "mild" hyperthermic versus "controlled" normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995; 31: 73-81.
18. Vaglini M, Andreola S, Attili A, et al. Hyperthermic anntiblastic perfusion in the treatment of cancer of the extremities. Tumori 1985; 71: 355-59.
19. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 150: 32-35.
20. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995; 19: 363-68.
21. Cavaliere R, Calabro A, Di Filippo F, et al. Prognosic parameters in limb recurrent melanoma treated with hyperthermic antiblastic perfusion. Proceedings of the International Conference on Regional Cancer Treatment, Ulm, 1987. G7: 163.
22. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551-61.
23. Kroon BBR, Klaase JM, Van Geel AN, Eggermont AMM. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4: 223-26.
24. Lindner P, Doubrovsky A, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9: 127-36.
25. De Wilt JHW, Lindnér P, Colman M, et al. Double isolated limb infusion with cytotoxic agents for recurrent and and metastatic limb melanoma. Eur J Cancer (in press).
26. Carswell EA, Old LJ, Kassel RL. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
27. Asher AL, Mule JJ, Reichert CM, et al. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963-74.
28. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 50-62.
29. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer 1993; 29A: 606-12.
30. Hill S, Fawcett WJ, Sheldon J, et al. Low dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80: 995-97.
31. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose TNF, gamma-IFN and melphalan. Cancer 1994; 73: 483-92.
32. Eggermont AMM, Liénard D, Schraffordt Koops H, et al. High dose tumor necrosis factor-alpha in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat 1995; 7: 32-36.
33. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14: 479-89.
34. Lienard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.
35. Brouckaert PGG, Leroux-Rouls GG, Guisez Y Tavernier J, Fiers W. In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneic murine melanoma. Int J Cancer 1996; 38: 763-69.
36. Fraker DL, Alexander HR, Andrich M, et al. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995; 1: 122.
37. Bartlett DL, Grace M, Alexander HR, et al. Isolated limb perfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997; 80: 2084-90.
38. McBride CM, Sugarbaker EV, Hickey RC. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 1975; 182: 316-24.
39. Schraffordt-Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1999; 16: 2906-12.
40. Hafström L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991; 9: 2091-94.
41. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977; 185: 555-64.
42. Muchmore JH, Carter RD, Krementz ET. Regional perfusion for malignant melanoma and soft tissue sarcoma: a review. Cancer Invest 1985; 3: 129-43.
43. Pommier RF, Moseley HS, Cohen J, et al. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities. Am J Surg 1988; 155: 667-71.
44. Klaase JM, Kroon BBR, Benckhuysen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64: 616-21.
45. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994; 73: 2140-46.
46. Eggermont AMM, Liénard D, Schraffordt Koops H, et al. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNF-α in combination with gamma-interferon and melphalan. In: Fiers W, Burrman WA (Eds). Tumor necrosis factor: molecular and cellular biology and clinical relevance. Basel: Karger, 1993: 239-43.
47. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-65.
48. Santinami M, Deraco M, Azzarelli A, et al. Treatment of recurrent sarcoma of the extremities by isolated perfusion using tumor necrosis factor alpha and melphalan. Tumori 1996; 82: 579-84.
49. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 1996; 224: 756-64.
50. Gutman M, Inbar , Lev-Shlush D, et al. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997; 79: 1129-37.
51. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Limb salvage by isolation limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proc Am Soc Clin Oncol 1999; 11: 497 (Abstr).
52. Rossi CR, Foletto M, Di Filippo F, et al. Soft tissue limb sarcomas: Italia clinical trials with hyperthermic antiblastic perfusion. Cancer 1999; 86: 1742-49.
53. Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26: 669-78.
54. Lans TE, de Wilt JHW, van Geel AN, Eggermont AMM. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. Ann Surg Oncol 2002; 9: 1004-09.
55. Etten van B, van Geel AN, de Wilt JHW, Eggermont AMM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003; 10: 32-37.
56. Vrouenraets BC, Eggermont AMM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001; 27: 390-95.
57. Olieman AF, Lienard D, Eggermont AM, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134: 303-07.
58. Bickels J, Manusama ER, Gutnam M, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999; 25: 509-14.
59. Lev-Chelouche D, Abu-Abeid S, Nakache R, et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery 1999; 126: 963-67.
60. Sijens PE, Eggermont AMM, Van Dijk P, Oudkerk M. P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFα + melphalan isolated limb perfusion. NMR Biomed 1995; 18: 215-24.
61. Renard N, Liénard D, Lespagnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFα). Int J Cancer 1994; 57: 656-63.
62. Nooijen PTGA, Eggermont AMM, Schalkwijk L, et al. Complete response of melanoma in-transit metastasis after isolated limb perfusion with tumor necrosis factor-alpha and melphalan without massive tumor necrosis: clinical and histopathological study of the delayed-type reaction patterns. Cancer Res 1998; 58: 4880-87.
63. Manusama ER, Nooijen PTGA, Stavast J, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83: 551-55.
64. Manusama ER, Stavast J, Durante NMC, et al. Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996; 22: 152-57.
65. De Wilt JHW, ten Hagen TLM, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000-03.
66. Veen vd AH, Wilt de JHW, Eggermont AMM, et al. TNF-α augments intratumoural concentration of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 2000; 82: 973-80.
67. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996; 74: 533-36.
68. Manusama ER, Nooijen PTGA, Stavast J, et al. Assessment of the role of neutrophils on the antitumor effect of TNFα in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res 1998; 78: 169-75.
69. DeWilt JHW, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor-alpha and melphalan in rats. Br J Cancer 1999; 80: 161-66.
70. Manusama ER, de Wilt JHW, ten Hagen TLM, et al. Toxicity and antitumor activity of inteferon-gamma alone and in combinations with TNF and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep 1999; 6: 173-77.
71. Seynhaeve ALB, de Wilt JHW, van Tiel SA, et al. Combination of actinomycin D with TNF-α in isolated limb perfusion results in improved tumour response in soft tissue sarcoma-bearing rats but is accompanied by severe dose limiting local toxicity. Br J Cancer 2002; 86: 1174-79.
72. DeWilt JHW, Manusama ER, van Etten B, et al. Inhibition of nitric oxide synthesis by L-NAME results in synergistic antitumour activity with melphalan and tumour necrosis factor-alpha-based isolated limb. Br J Cancer 2000; 83: 1176-11.
73. Roos de WK, de Wilt JHW, van der Kaaden ME, et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 2000; 232: 814-21.
74. De Wilt JHW, Bout A, Eggermont AMM, et al. Adenovirus-mediated IL-3 gene transfer using isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Genether 2001; 12: 489-502.
75. Ten Hagen TLM, FJ Lejeune, Eggermont AMM. TNF is here to stay - revisited. Trends Immunol 2001; 22: 127-29.